Shares of Israel Chemicals Ltd. (NYSE:ICL) have received a consensus broker rating score of 3.00 (Hold) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a hold recommendation.
Brokers have set a 12-month consensus price objective of $6.63 for the company and are anticipating that the company will post $0.12 EPS for the current quarter, according to Zacks. Zacks has also assigned Israel Chemicals an industry rank of 179 out of 265 based on the ratings given to related companies.
Shares of Israel Chemicals (NYSE:ICL) opened at 4.05 on Monday. Israel Chemicals has a one year low of $4.01 and a one year high of $7.70. The company has a market capitalization of $5.15 billion and a price-to-earnings ratio of 10.33. The company’s 50 day moving average is $4.64 and its 200 day moving average is $5.76.
Israel Chemicals (NYSE:ICL) last posted its earnings results on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.13 by $0.01. The firm had revenue of $1.38 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Israel Chemicals’s quarterly revenue was down 11.6% on a year-over-year basis. Equities research analysts predict that Israel Chemicals will post $0.48 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 16th. Stockholders of record on Tuesday, December 1st were given a $0.0659 dividend. The ex-dividend date was Tuesday, December 1st. This represents a $0.26 dividend on an annualized basis and a dividend yield of 6.51%.
ICL has been the subject of several recent research reports. Goldman Sachs downgraded shares of Israel Chemicals from a “neutral” rating to a “sell” rating in a research note on Tuesday, September 22nd. Zacks Investment Research upgraded shares of Israel Chemicals from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Monday, September 28th. Finally, Barclays cut their price objective on shares of Israel Chemicals from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Friday, November 20th.
For more information about research offerings from Zacks Investment Research, visit Zacks.com